|
|
| (19 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT [[Ibandronate]] |
| |authorTag={{DB}}
| |
| |genericName=Ibandronate sodium
| |
| |aOrAn=a
| |
| |drugClass=bone density conservation agent
| |
| |indicationType=prophylaxis
| |
| |indication=osteoporosis
| |
| |adverseReactions=hypertension,abdominal pain, diarrhea, indigestion, nausea,
| |
| back ache, pain in limb, headache, bronchitis, upper respiratory infection
| |
| |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
| |
| |fdaLIADAdult=====Treatment and Prevention of Postmenopausal Osteoporosis====
| |
| | |
| *BONIVA is indicated for the treatment and prevention of osteoporosis in postmenopausal women. BONIVA increases bone mineral density (BMD) and reduces the incidence of vertebral fractures.
| |
| | |
| '''Important Limitations of Use'''
| |
| | |
| *The optimal duration of use has not been determined. The safety and effectiveness of BONIVA for the treatment of osteoporosis are based on clinical data of three years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.
| |
| *Dosing information:
| |
| :* The dose of BONIVA is one 150 mg tablet taken once monthly on the same date each month.
| |
| |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Ibandronic acid in adult patients.
| |
| |offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Ibandronic acid in adult patients.
| |
| |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Ibandronic acid in pediatric patients.
| |
| |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Ibandronic acid in pediatric patients.
| |
| |contraindications=BONIVA is contraindicated in patients with the following conditions:
| |
| | |
| *Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia.
| |
| *Inability to stand or sit upright for at least 60 minutes.
| |
| *Hypocalcemia.
| |
| *Known hypersensitivity to BONIVA or to any of its excipients. Cases of anaphylaxis have been reported.
| |
| | |
| |administration='''Dosage Information'''
| |
| | |
| *The dose of BONIVA is one 150 mg tablet taken once monthly on the same date each month.
| |
| | |
| '''Important Administration Instructions'''
| |
| | |
| Instruct Patients to do the following:
| |
| | |
| *Take BONIVA at least 60 minutes before the first food or drink (other than water) of the day or before taking any oral medication or supplementation, including calcium, antacids, or vitamins to maximize absorption and clinical benefit, (see DRUG INTERACTIONS [7.1]). Avoid the use of water with supplements including mineral water because they may have a higher concentration of calcium.
| |
| *Swallow BONIVA tablets whole with a full glass of plain water (6 to 8 oz) while standing or sitting in an upright position to reduce the potential for esophageal irritation. Avoid lying down for 60 minutes after taking BONIVA. Do not chew or suck the tablet because of a potential for oropharyngeal ulceration.
| |
| *Do not eat, drink anything except plain water, or take other medications for at least 60 minutes after taking BONIVA.
| |
| | |
| '''Recommendations for Calcium and Vitamin D Supplementation'''
| |
| | |
| *Instruct patients to take supplemental calcium and vitamin D if their dietary intake is inadequate. Avoid the use of calcium supplements within 60 minutes of BONVIA administration because co-administration of BONIVA and calcium may interfere with the absorption of ibandronate sodium.
| |
| | |
| '''Administration Instructions for Missed Once-Monthly Doses'''
| |
| | |
| *If the once-monthly dose is missed, instruct patients to do the following:
| |
| | |
| :*If the next scheduled BONIVA day is more than 7 days away, take one BONIVA 150 mg tablet in the morning following the date that it is remembered.
| |
| :*If the next scheduled BONIVA day is only 1 to 7 days away, wait until the subsequent month's scheduled BONIVA day to take their tablet.
| |
| | |
| *For subsequent monthly doses for both of the above scenarios, instruct patients to return to their original schedule by taking one BONIVA 150 mg tablet every month on their previous chosen day.
| |
| | |
| '''DOSAGE FORMS AND STRENGTHS'''
| |
| | |
| *BONIVA 150 mg tablets: white, oblong, engraved with "BNVA" on one side and "150" on the other side.
| |
| |alcohol=Alcohol-Ibandronic acid interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| }}
| |